Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Haemopoietic growth factors.

S Devereux¹, D Linch

¹Kent and Canterbury General Hospital.

The Quarterly Journal of Medicine

|June 1, 1990

Summary

Recombinant haemopoietic growth factors show promise for cancer therapy and infections. However, rigorous clinical trials are essential to confirm their benefits and manage potential toxicities like thrombocytopenia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Intraoperative needlescopy facilitates complete urolith removal during open cystotomy in dogs and cats: 19 cases.

The Journal of small animal practice·2026

Same author

Calcaneotibial screws for immobilisation of the tarsocrural joint of dogs in extension: effect of the angle of screw placement on the force to failure in a canine cadaveric model.

New Zealand veterinary journal·2021

Same author

Author Correction: Mir142 loss unlocks IDH2<sup>R140</sup>-dependent leukemogenesis through antagonistic regulation of HOX genes.

Scientific reports·2021

Same author

Mir142 loss unlocks IDH2<sup>R140</sup>-dependent leukemogenesis through antagonistic regulation of HOX genes.

Scientific reports·2020

Same author

Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity.

Leukemia·2017

Same author

Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Area of Science:

Biotechnology
Hematology
Oncology

Background:

Recombinant haemopoietic growth factors enable advanced in vitro and in vivo research.
Previous studies align with in vitro expectations, suggesting therapeutic potential.

Purpose of the Study:

To evaluate the clinical value and applications of haemopoietic growth factors.
To highlight the necessity of rigorous clinical trials for defining efficacy and safety.

Main Methods:

Review of existing in vitro and in vivo studies.
Emphasis on the need for randomized controlled trials with clinical end-points.
Discussion of challenges in trial design for specific conditions like chemotherapy-induced neutropenia.

Main Results:

Haemopoietic growth factors offer potential for cancer therapy by enabling dosage escalation and improving survival.
Managing chemotherapy-induced neutropenia may benefit from these factors, though mortality benefits require large studies.
Thrombocytopenia is a potential limitation, necessitating treatments like thrombopoietin.

Conclusions:

Careful patient selection and large-scale trials are crucial for realizing the benefits of haemopoietic growth factors in cancer therapy.
Further research into combinations of factors may enhance efficacy and reduce toxicity.
The use of haemopoietic growth factors as adjuncts in treating severe infections requires complex trial designs.

Related Experiment Videos